- Powder for inhalation 50 mcg (as salmeterol xinafoate)
Produces bronchodilation by relaxing bronchial smooth muscle through beta-2 receptor stimulation.
Salmeterol acts locally in the lung. Plasma levels do not predict therapeutic effect. Depending on dose, T max is 20 min and mean C max is 167 pg/mL.
Protein binding is 96%; xinafoate moiety is greater than 99%.
Extensively metabolized by hydroxylation.
Eliminated in feces (60%) and urine (25%); half—life is 5.5 days. Xinafoate moiety half-life is 11 days.
Special PopulationsRenal Function Impairment
Has not been studied in patients with renal impairment.Hepatic Function Impairment
May lead to accumulation of salmeterol in plasma.Elderly
Has not been studied in elderly patients.
Indications and Usage
Treatment of asthma and prevention of bronchospasm; prevention of exercise-induced bronchospasm (EIB); maintenance treatment of bronchospasm associated with COPD (including emphysema and chronic bronchitis).
Use without a concomitant long-term asthma control medication (eg, inhaled corticosteroid) for the treatment of asthma; hypersensitivity to salmeterol or product components.
Dosage and AdministrationAsthma/Bronchospasm
Adults and Children 4 y of age and older
Inhalation 1 inhalation (50 mcg) twice daily, approximately 12 h apart.EIB
Adults and Children 4 y of age and older
Inhalation 1 inhalation at least 30 min before exercise; additional doses should not be used for at least 12 h.COPD
Inhalation 1 inhalation (50 mcg) twice daily, approximately 12 h apart.
- For oral inhalation only.
- When initiating therapy in patients receiving oral or inhaled corticosteroids, continue patients on a suitable dose of corticosteroids; make any changes in corticosteroid dosage only after clinical evaluation.
- Do not exhale into the inhalation device.
- Only activate and use the inhalation device in a level, horizontal position.
- Do not use a spacer.
- Do not exceed recommended dosage.
Store between 68° and 77°F in a dry place. Protect from direct heat or sunlight. Discard 6 wk after removal from moisture-protective foil pouch or when the dose indicator reads “0.”
Drug InteractionsBeta-adrenergic blockers (eg, atenolol, propranolol)
Pulmonary effects of salmeterol may be blocked by beta-blockers and may produce severe bronchospasm in patients with COPD. If coadministration cannot be avoided, cardioselective beta-blockers could be considered, but administer them with caution.CYP3A4 strong inhibitors (eg, atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin)
Salmeterol plasma concentrations may be elevated, increasing the pharmacologic effects and risk of adverse reactions. In addition, coadministration of salmeterol and ketoconazole may increase the QTc interval. Because of the potential increased risk of CV adverse reactions, coadministration of salmeterol and strong CYP3A4 inhibitors is not recommended.Erythromycin
Coadministration may increase salmeterol C max , resulting in increases in heart rate and QTc interval. Coadminister with caution and closely monitor for CV adverse reactions.Long-acting beta-2 agonists (eg, formoterol)
Other long-acting beta-2 agonists will have additive effects with salmeterol, increasing the risk of asthma-related death. Do not use salmeterol with other medications containing a long-acting beta-2 agonist.MAOIs (eg, phenelzine), linezolid, tricyclic antidepressants (TCAs) (eg, amitriptyline)
May increase CV effects of salmeterol. If coadministration cannot be avoided, give salmeterol with extreme caution to patients being treated with MAOIs or TCAs or within 2 wk of discontinuing an MAOI or TCA.Non potassium–sparing diuretics (eg, loop diuretics [eg, furosemide] or thiazide diuretics [eg, chlorothiazide])
ECG changes and hypokalemia associated with diuretics may worsen with coadministration, especially when the recommended dose of the beta-agonist is exceeded. Coadminister with caution.
Hypertension (4%); palpitations, tachycardia; arrhythmias, including atrial fibrillation, extrasystoles, and supraventricular tachycardia (postmarketing).
Headache (17%); dizziness (4%); anxiety, migraine, nervousness, paresthesia, sleep disturbance (1% to 3%); tremor.
Rash (4%); urticaria (3%); contact dermatitis, eczema (1% to 3%); photodermatitis (1% to 2%).
Nasal sinus congestion, pallor (9%); throat irritation (7%); pharyngitis (6%); rhinitis (5%); ear signs/symptoms, nasal blockage/congestion, sinusitis (4%); conjunctivitis, keratitis, sinus headache (1% to 3%).
Nausea/vomiting (3%); dental pain, dyspepsia, GI infections, hyposalivation, oral/throat candidiasis, oral mucosal abnormality (1% to 3%); GI signs/symptoms (1% to 2%).
Immediate hypersensitivity reactions (eg, angioedema, bronchospasm, rash); anaphylaxis (postmarketing).
Skeletal muscle pain (12%); muscle cramps/spasms (3%); arthralgia, articular rheumatism, bone/skeletal pain, inflammation, muscle pain, muscle stiffness, pain in joints, tightness, rigidity (1% to 3%).
Bronchitis, tracheitis (7%); cough, viral respiratory tract infection (5%); asthma (4%); lower respiratory signs/symptoms (1% to 2%); irritation or swelling (including stridor or choking), laryngeal spasm, oropharyngeal irritation, paradoxical bronchospasm, serious exacerbations of asthma (some fatal) (postmarketing).
Influenza (5%); edema, fever, hyperglycemia, localized aches and pains, pain, swelling (1% to 3%).
Long-acting beta-2 adrenergic agonists increase the risk of asthma-related death. Salmeterol is contraindicated when used without a concomitant long-term asthma control medication (eg, inhaled corticosteroid) for the treatment of asthma. Only use salmeterol as additional therapy for patients not adequately controlled on other asthma-controller medications (eg, inhaled corticosteroids). Do not use salmeterol for patients whose asthma is adequately controlled on low- or medium-dose inhaled corticosteroids.
In children and adolescents, data suggests that long-acting beta-2 adrenergic agonists increase the risk of asthma-related hospitalization. For children and adolescents with asthma who require addition of a long-acting beta-2 adrenergic agonist to an inhaled corticosteroid, a fixed-dose combination product containing both an inhaled corticosteroid and a long-acting beta-2 adrenergic agonist should ordinarily be used.
Monitor for signs of worsening asthma. Observe special caution in elderly patients with CV disease. Monitor patients with hepatic impairment closely.
Category C .
Safety and efficacy for children younger than 4 y of age not established.
Observe special caution in elderly patients with CV disorders.
Allergic reactions can occur after administration.
Closely monitor these patients.
Acute or worsening asthma events
Do not use salmeterol to treat acute symptoms; short-acting beta-2 adrenergic agonists should be used.
Use with caution in patients with CV disease (eg, cardiac arrhythmias, coronary insufficiency, hypertension); toxic symptoms may occur. ECG changes (eg, flattening of T wave, QTc prolongation, ST segment depression) have occurred; clinical significance is unknown.
Paradoxical bronchospasm and cardiac arrest have been associated with excessive inhalant use. The recommended dosage should not be exceeded.
Decreases in potassium levels may occur.
Life-threatening paradoxical bronchospasm may occur.
Use with caution in patients with convulsive disorders or thyrotoxicosis, or who are unusually responsive to sympathomimetic amines.
Arrhythmias and/or tachycardia, cardiac arrest, death, headache, hyperglycemia, hypokalemia, muscle cramps, palpitations, prolongation of the QTc interval, tremor.
- Instruct patients to read the Medication Guide before starting therapy and with each refill.
- Instruct patient on the proper storage, handling, and use of the dry powder inhaler, referring to the patient information leaflet included with the medication.
- Advise patient that medication should never be administered with a spacer device.
- Caution patient not to exceed prescribed dose. Inform patient that medication is still inhaled even if it is not tasted or felt when delivered.
- Instruct patient not to stop the medication once symptoms have been controlled. Continued daily use is necessary to continue control of symptoms.
- Advise patient not to change the dose or stop using unless advised by health care provider.
- Caution patient not to use other salmeterol-containing products or other long-acting bronchodilators while using salmeterol.
- Warn patient that salmeterol is a maintenance medication and is not to be used to treat an acute asthma attack. “Rescue medication” (short-acting bronchodilator) must be used to obtain rapid relief of asthma symptoms.
- Advise patient using salmeterol for prevention of EIB to take medication at least 30 min before exercise and to wait 12 h before using again.
- Advise patient that medication does not replace inhaled or oral corticosteroids and to continue to use as prescribed by health care provider.
- Advise patient not to increase dose and to inform health care provider if symptoms do not improve or worsen, if more inhalations than usual of the short-acting bronchodilator are needed, or if the short-acting bronchodilator appears to become less effective.
- Advise patient to carry medical identification (eg, card, bracelet) if they experience acute severe asthma attacks requiring rapid systemic treatment.
- Advise patient to report the following symptoms to health care provider: chest pain, nervousness, palpitations, persistent cough, rapid heart rate, sore throat or mouth, tremor, worsening asthma symptoms.
Copyright © 2009 Wolters Kluwer Health.
More Salmeterol resources
- salmeterol MedFacts Consumer Leaflet (Wolters Kluwer)
- salmeterol Inhalation Advanced Consumer (Micromedex) - Includes Dosage Information
- Salmeterol Xinafoate Monograph (AHFS DI)
- Serevent Prescribing Information (FDA)
- Serevent Consumer Overview
- Serevent Diskus Prescribing Information (FDA)
- Serevent diskus